Introduction
Chronic myeloid leukemia (CML) is a clonal disease characterized by the Philadelphia chromosome, which contains the BCR-ABL1 fusion gene that encodes the P210 BCR-ABL1 protein. Typically, patients with CML experience three phases: a chronic phase (CP), an accelerated phase (AP), and a blast phase (BP), where the AP and BP involve progression of the disease. Patients who progress to BP receive standard treatment similar to that used for acute leukemia; but the effect is insufficient and the patients have a poor prognosis. 1, 2 The development of CML is very complex and involves gene mutations, chromosomal variations, and epigenetic regulation of genes. 3 In contrast to genetic changes, epigenetic changes refer to hereditary changes in gene expression without changes in DNA sequence, such as DNA methylation, chroma-
Cell culture
KCL22 and K562 cells were from Shanghai Hong Shun Biotechnology Co., Ltd. (Shanghai, China). The use of K562 and KCL22 cells was confirmed by the ethics committee of the Department of Hematology of the Second Hospital of Hebei Medical University. KCL22 cells were cultured in Iscove's Modified Dulbecco's Medium (IMDM; Thermo Fisher Scientific, Waltham, MA, USA) supplemented with 10% fetal bovine serum (FBS; Clark Bioscience, Claymont, DE, USA), 100 units/mL penicillin, and 100 µg/mL streptomycin. K562 cells were maintained in the RPMI 1640 medium (Thermo Fisher Scientific) supplemented with 10% FBS, 100 units/ mL penicillin, and 100 µg/mL streptomycin.
Cell treatment
5-Azacytidine was purchased from ApexBio (Houston, TX, USA). KCL22 and K562 cells were seeded in 6-well plates at 5×10 6 cells/well. MTT assays were performed to measure the EC50 concentrations of 5-azacytidine. The K562 and KCL22 cells were treated with 5-azacytidine at the EC50 values. KCL22 cells were treated with 60, 80, and 100 µmol/L 5-azacytidine; K562 cells were treated with 40, 60, and 80 µmol/L 5-azacytidine. The cells were treated for 48 hours.
MTT assays
We seeded KCL22 and K562 cells into 96-well plates (1×10 4 cells/well) after transfection and cultured them for 0, 24, 48, 72, 96, and 120 hours using IMDM with 10% FBS at 37°C and RPMI 1640 with 10% FBS. Proliferation of the KCL22 and K562 cells was determined with an MTT assay. Briefly, following cell culture, 10 µL of MTT reagent (Sigma-Aldrich Co., St Louis, MO, USA) was added to Reverse: 5′-CTagCCgCCgTCTaTaCTaCCggCT-3′ DnMT1
Forward: 5′-agaCaCTCgCTCagCTTCTTg-3′ 116
Reverse: 5′-CaaTTgCTgCTgggaTTCaTC-3′ DnMT3a
Forward: 5′-CTgCTTTgTaTTCCCTTTTgCa-3′ 141
Reverse: 5′-TTgaTTTCTCCTggCTgTCTC-3′ hDaC1
Forward: 5′-CCTCCCgagTgaagTCaTCgTgg-3′ 181
Reverse: 5′-ggaCaggTgCTTCaTCagCTCg-3′ Pi3K
Forward: 5′-aCCaCaCgTTCCTaagCTgg-3′ 124
Reverse: 5′-TCCCTgCaCgCagagaTTTT-3′ aKT Forward: 5′-aaCTaCaaCTTCTTCCCTCgCaa-3′ 109
Reverse: 5′-CaaagTTaTgTCCaCTgTCTCT-3′ lsD1
Forward: 5-CaTCaCCgTagTCCCaTTg-3′ 175
Reverse: 5-aaaTTCCCCaCTTCgCTTgg-3′ eZh2
Forward: 5′-CCaCCCTTgTgCTCTTCCCTg-3′ 100
Reverse: 5′-TCTgCCaCCCgagTgTaaCCa-3′ mTOR Table 3 .
Western blot (WB)
Cells were lysed using radioimmunoprecipitation assay (RIPA) buffer, and protein was obtained. The protein concentration was determined using a BCA protein assay kit (Thermo Fisher Scientific). Proteins were separated on 8%-15% SDS-PAGE gels, and the separated bands were electrotransferred to polyvinylidene fluoride (PVDF) membranes (Amersham Pharmacia, Piscataway, NJ, USA). The PVDF membranes were blocked with 5% non-fat skim milk at room temperature and probed with antibodies targeting PI3K (1:1,000), AKT (1:3,000), mTOR (1:2,000), pPI3K (1:3,000), pAKT (1:3,000), pmTOR (1:1,000), EZH2 (1:2,000), LSD1 (1:2,000), DNMT1 (1:2,000), DNMT3A (1:3,000), HDAC1 (1:2,000) and ACTB (1:5,000) (Abcam, Cambridge, MA, USA). The diluted corresponding secondary antibody was incubated with the membranes at room temperature for 1 hour, and the membranes were then rinsed three times for 5 minutes each with tris-buffered saline. Protein expression was examined using a BioSpectrum Imaging System (UVP, LLC, Upland, CA, USA).
Rna pull-down assay
HOTAIR-binding proteins were determined using a Pierce Magnetic RNA-Protein Pull-Down Kit (Thermo Fisher Scientific) according to the manufacturer's protocols. HOTAIR sense and HOTAIR antisense lncRNAs were constructed and incubated with the protein from KCL22 cells, and 100 mL of silver staining solution was added to the HOTAIR sense and HOTAIR antisense lncRNA and protein mixture. The total protein was then collected for mass spectrometry sequencing.
Rna immunoprecipitation
RNA immunoprecipitation was performed using the Magna RIP Kit (EMD Millipore, Billerica, MA, USA). Complete KCL22 cell lysates were prepared according to the manufacturer's instructions and contained phosphatase and proteinase inhibitors. Next, we evaluated the connection and configuration of the antibody beads, antibody beads suspension was mixed with the sample after thawing and placed on a table at 4°C for overnight incubation. Immunoprecipitation was completed after the suspension was placed on the magnetic frame and washed with washing buffer at least six times. Finally, the immune co-precipitation products were collected, and RNA was extracted and purified to determine the abundance of the target RNA.
luciferase assay
In the dual-luciferase assay, we seeded HOTAIR and negative control (NC) cells into 24-well plates and co-transfected the cells with 0.4 mg of firefly luciferase reporter vector, 0.08 mg of Renilla luciferase pRL-TK (Promega Corporation, Fitchburg, WI, USA), and control vector according to the manufacturer's instructions. At 48 hours after transfection, the cells were lysed. Luciferase activity was measured by a dual-luciferase reporter gene assay system (Promega Corporation). Renilla luciferase activity was determined relative to the standardized fluorescence activity of firefly luciferase. All assays were repeated at least three times.
statistical analysis
The data are expressed as mean±SD and were analyzed using SPSS 19.0 software (IBM Corporation, Armonk, NY, USA). Significant differences between groups were analyzed 
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Regulation of hOTaiR in advanced chronic myeloid leukemia healthy donors (P<0.05), and there was no significant difference in methylation rates between CP CML and healthy donors (P>0.05; Figure 3 ). The advanced stages of CML were associated with a high methylation rate. mRna and protein levels after drug treatment 
hOTaiR knockdown inhibited proliferation and promoted apoptosis
To examine the biological role of lncRNA HOTAIR in CML blast crisis, we first determined the expression of HOTAIR in BMMCs and K562 and KCL22 cells; the result indicated that the expression of HOTAIR was higher in KCL22 and K562 cells than in BMMCs (P<0.05; Figure S1A ). Next, sh-HOTAIR and sh-control were synthesized and transfected into KCL22 and K562 cells; the results indicated that the expression of HOTAIR was lower in the knockdown group than in the control group (P<0.05; Figure S1B 
hOTaiR interacts with miR-143
Competing endogenous RNAs are lncRNAs that act as sponges to bind miRNAs and prevent them from performing normal regulatory activities. To investigate whether HOTAIR acts in this way, a luciferase reporter assay was performed to determine whether HOTAIR binds miR-143. The results indicated that transfection with miR-143 mimic decreased the luciferase activity of HOTAIR wild-type plasmids in KCL22 cells (P<0.05; Figure 6B ) but had no effect on mutant-type plasmids (P>0.05; Figure 6A ). HOTAIR was able to interact with miR-143 ( Figure 6D ).
hOTaiR interacts with eZh2 and lsD1
To determine whether the lncRNA HOTAIR binds protein, RNA pull-down and RIP assays were performed. The results 
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Regulation of hOTaiR in advanced chronic myeloid leukemia showed that EZH2 and LSD1 interacted with the HOTAIR lncRNA (P<0.05; Figure 6C ). EZH2 and LSD1 were able to interact with HOTAIR.
Overexpression of miR-143 inhibited proliferation and promoted apoptosis
To examine the influence of miR-143 on cell proliferation and apoptosis of KCL22 and K562, we first measured miR-143 expression levels in KCL22, K562, and BMMCs. The result showed that miR-143 expression levels were lower in KCL22 and K562 cells than in BMMCs ( Figure S1D) . Next, the miR-143 mimic was transfected into KCL22 and K562 cells ( Figure S1E and F) ; proliferation assays were performed to assess the influence of miR-143 on proliferation of KCL22 and K562 cells. We found that cell viability of KCL22 cells decreased 96 and 120 hours after transfection with the miR-143 mimic (P<0.05; Figure 7A and B), whereas that of K562 cells was reduced 120 hours after transfection with the miR-143 mimic (P<0.05; Figure 7A and B) . Flow cytometry was then performed to determine the influence of miR-143 on KCL22 and K562 apoptosis; the results indicated that miR-143 overexpression promoted apoptosis (P<0.05; Figure 7A . in KCl22 cells, overexpression of miR-143 had no effect on total Pi3K, aKT, and mTOR protein levels (▼▲ P>0.05) but decreased phosphorylated Pi3K, aKT, and mTOR protein levels (◆✩ P<0.05). (D) in K562 cells, Pi3K, aKT, and mTOR mRna levels were decreased in the overexpression group (★✩◆ P<0.05); in K562 cells, overexpression of miR-143 had no effect on total Pi3K, aKT, and mTOR protein levels (◆▼ P>0.05) but decreased phosphorylated Pi3K, aKT, and mTOR protein levels (▲✩ P<0.05).
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li and luo pression of miR-143 decreased PI3K/AKT pathway mRNA levels (P<0.05) and had no effect on total PI3K/AKT pathway protein levels (P>0.05), but decreased levels of phosphorylated PI3K/AKT pathway proteins (P<0.05; Figures 5 and 7 ). Both knockdown of HOTAIR and overexpression of miR-143 influenced phosphorylated PI3K/AKT pathway proteins.
Discussion
CML accounts for ~10% of all types of leukemia, and although it can occur in any age group, it most often occurs in patients aged 55-70 years. The incidence of CML is higher in males than in females. 1 The Philadelphia chromosome, characterized by the presence of the BCR-ABL1 fusion gene, is the most common chromosomal abnormality in CML. This fusion gene encodes a constitutively active tyrosine kinase signaling protein; this uncontrolled activity leads to CML. 22 Although tyrosine kinase inhibitors have improved the 5-year survival rate of CML, some patients, due to drug resistance or an inability to tolerate tyrosine kinase inhibitors, still progress to AP and BP of CML. 23 Epigenetic gene regulation and noncoding RNA take part in this progression. 24 As a noncoding RNA, the lncRNA HOTAIR encodes no protein. It promotes proliferation of cervical cancer by targeting miR-143 and proliferation of breast cancer by upregulating Bcl-w. 25, 26 HOTAIR-mediated DNA methylation contributes to the progress of osteosarcoma by targeting miR126. 27 In our study, high levels of the HOTAIR were found in advanced stages of CML and were inversely proportional to miR-143 levels. We also found higher methylation promoter rates of HOTAIR and miR-143 in advanced CML. Thus, we speculated that high levels of HOTAIR lncRNA, low levels of miR-143, and higher methylation promoter rates of HOTAIR and miR-143 were associated with CML progression.
Methylation of DNA at CpG islands and histone modification are two mechanisms that lead to gene silencing, which affects the gene promoter. 4 The DNMT family, which includes DNMT1, DNMT3A, and DNMT3B, mediates CpG island methylation, 7 and the HDAC family regulates histone deacetylation. 28 The discovery of LSD1 was an important step in epigenetics research; methylation and other chemical modifications of histone lysine are dynamic regulatory processes. LSD1 has been accepted as an important prognostic factor in hepatocellular carcinoma and breast cancer. 29, 30 EZH2 belongs to polycomb repressive complex 2, 31 is highly conserved, and can inhibit the transcription of downstream target genes. High levels of EZH2 are associated with poor prognosis in many types of cancer, such as hepatocellular carcinoma and pancreatic cancer. 32, 33 Therefore, we examined DNMT1, DNMT3A, HDAC1, EZH2, and LSD1 mRNA and protein levels in different phases of CML and in healthy donors. We also measured the mRNA levels of HOTAIR and miR-143 in different phases of CML and in healthy donors. The results indicated that mRNA and protein levels of DNMT1, DNMT3A, HDAC1, EZH2, and LSD1 were higher in advanced CML and that mRNA levels of HOTAIR were higher and levels of miR-143 were lower in advanced CML. Thus, we concluded that high levels of EZH2 and LSD1 at least partly account for CML progression.
Next, we treated K562 and KCL22 cells with different concentrations of 5-azacytidine. Treatment increased miR-143 levels and decreased levels of DNMT1, DNMT3A, HDCA1, EZH2, LSD1, and HOTAIR in both KCL22 and K562 cell lines.
To further examine the role of HOTAIR and miR-143 in CML blast crisis, we knocked down HOTAIR and overexpressed miR-143. Both modifications inhibited proliferation and promoted apoptosis in KCL22 and K562 cells. We then performed RNA pull-down and RIP assays to study the regulation of HOTAIR in KCL22 cells and observed that EZH2 and LSD1 interacted with HOTAIR. Thus, we speculated that EZH2 and LSD1 may regulate HOTAIR in CML blast crisis.
PI3K/AKT signaling plays a critical role in many hematological diseases, including acute myeloid leukemia and CML. [34] [35] [36] Our results showed that silencing of HOTAIR and overexpression of miR-143 decreased phosphorylation of PI3K/AKT/mTOR proteins; thus, we concluded that the PI3K/AKT pathway is a target for HOTAIR and miR-143.
Conclusion
HOTAIR is a potential therapeutic target for CML blast crisis, and demethylation drugs may represent a new treatment strategy.
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